Clinical Trial Detail

NCT ID NCT02130557
Title A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Recruitment Completed
Gender both
Phase Phase III
Variant Requirements No
Sponsors Avillion Development 1 Limited
Indications

chronic myeloid leukemia

Therapies

Bosutinib

Imatinib

Age Groups: adult

No variant requirements are available.